From Melanocyte to Metastatic Malignant Melanoma

Overview

Journal Dermatol Res Pract

Publisher Wiley

Specialty Dermatology

Date 2010 Oct 12

PMID 20936153

Citations 50

Authors

Bizhan Bandarchi

Linglei Ma

Roya Navab

Arun Seth

Golnar Rasty

Affiliations

Soon will be listed here.

Abstract

Malignant melanoma is one of the most aggressive malignancies in human and is responsible for almost 60% of lethal skin tumors. Its incidence has been increasing in white population in the past two decades. There is a complex interaction of environmental (exogenous) and endogenous, including genetic, risk factors in developing malignant melanoma. 8-12% of familial melanomas occur in a familial setting related to mutation of the CDKN2A gene that encodes p16. The aim of this is to briefly review the microanatomy and physiology of the melanocytes, epidemiology, risk factors, clinical presentation, historical classification and histopathology and, more in details, the most recent discoveries in biology and genetics of malignant melanoma. At the end, the final version of 2009 AJCC malignant melanoma staging and classification is presented.

Citing Articles

Evaluation of P53 immunostaining in patients with cutaneous melanoma.

Meevassana J, Mittrakulkij C, Toworrakul P, Saensuk W, Kamolratanakul S, Siritientong T Biomed Rep. 2023; 20(1):8.

PMID: 38124769 PMC: 10731165. DOI: 10.3892/br.2023.1696.

Exploring the Complex and Multifaceted Interplay between Melanoma Cells and the Tumor Microenvironment.

Kuras M Int J Mol Sci. 2023; 24(18).

PMID: 37762707 PMC: 10531837. DOI: 10.3390/ijms241814403.

Understanding Real-World Treatment Patterns and Clinical Outcomes among Metastatic Melanoma Patients in Alberta, Canada.

OSullivan D, Boyne D, Gogna P, Brenner D, Cheung W Curr Oncol. 2023; 30(4):4166-4176.

PMID: 37185430 PMC: 10136717. DOI: 10.3390/curroncol30040317.

Structure-Based Virtual Screening of Furan-1,3,4-Oxadiazole Tethered -phenylacetamide Derivatives as Novel Class of hTYR and hTYRP1 Inhibitors.

Irfan A, Faisal S, Ahmad S, Al-Hussain S, Javed S, Zahoor A Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986444 PMC: 10059052. DOI: 10.3390/ph16030344.

Cytotoxic Effects of Ethanolic Extract of Polypodium Vulgare on Human Malignant Melanoma Cell Line.

Tabeshpour J, Shakiban D, Qobadi A, Aghazadeh E, Yousefsani B Asian Pac J Cancer Prev. 2023; 24(1):275-281.

PMID: 36708577 PMC: 10152838. DOI: 10.31557/APJCP.2023.24.1.275.

References

Rockley P, Trieff N, Wagner Jr R, Tyring S . Nonsunlight risk factors for malignant melanoma. Part I: Chemical agents, physical conditions, and occupation. Int J Dermatol. 1994; 33(6):398-406. DOI: 10.1111/j.1365-4362.1994.tb04038.x. View

Whiteman D, Green A . Melanoma and sun exposure: where are we now?. Int J Dermatol. 1999; 38(7):481-9. DOI: 10.1046/j.1365-4362.1999.00712.x. View

Johnson T, Bradford C, Gruber S, Sondak V, Schwartz J . Staging workup, sentinel node biopsy, and follow-up tests for melanoma: update of current concepts. Arch Dermatol. 2004; 140(1):107-13. DOI: 10.1001/archderm.140.1.107. View

Marks R . Epidemiology of melanoma. Clin Exp Dermatol. 2000; 25(6):459-63. DOI: 10.1046/j.1365-2230.2000.00693.x. View

van der Rhee H, van Westering R, Coebergh J . Increase in and stabilization of incidence and mortality of primary cutaneous malignant melanoma in Western Netherlands, 1980-95. Br J Dermatol. 1999; 140(3):463-7. DOI: 10.1046/j.1365-2133.1999.02710.x. View

Degenhardt Y, Huang J, Greshock J, Horiates G, Nathanson K, Yang X . Distinct MHC gene expression patterns during progression of melanoma. Genes Chromosomes Cancer. 2009; 49(2):144-54. PMC: 2796267. DOI: 10.1002/gcc.20728. View

Naldi L, Lorenzo Imberti G, Parazzini F, Gallus S, La Vecchia C . Pigmentary traits, modalities of sun reaction, history of sunburns, and melanocytic nevi as risk factors for cutaneous malignant melanoma in the Italian population: results of a collaborative case-control study. Cancer. 2000; 88(12):2703-10. DOI: 10.1002/1097-0142(20000615)88:12<2703::aid-cncr8>3.0.co;2-q. View

Oka M, Kikkawa U . Protein kinase C in melanoma. Cancer Metastasis Rev. 2005; 24(2):287-300. DOI: 10.1007/s10555-005-1578-8. View

Yang J, Price M, Li G, Bar-Eli M, Salgia R, Jagedeeswaran R . Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res. 2009; 69(19):7538-47. PMC: 2762355. DOI: 10.1158/0008-5472.CAN-08-4626. View

10.

Cohen L . Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 1995; 33(6):923-36; quiz 937-40. DOI: 10.1016/0190-9622(95)90282-1. View

11.

Cowan J, Halaban R, Francke U . Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. J Natl Cancer Inst. 1988; 80(14):1159-64. DOI: 10.1093/jnci/80.14.1159. View

12.

Beral V, Evans S, Shaw H, MILTON G . Cutaneous factors related to the risk of malignant melanoma. Br J Dermatol. 1983; 109(2):165-72. DOI: 10.1111/j.1365-2133.1983.tb07077.x. View

13.

Dennis L . Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology, and end results program registry. Arch Dermatol. 1999; 135(3):275-80. DOI: 10.1001/archderm.135.3.275. View

14.

Kelly J . Melanoma in the elderly--a neglected public health challenge. Med J Aust. 1998; 169(8):403-4. View

15.

Ringborg U, Andersson R, Eldh J, Glaumann B, Hafstrom L, Jacobsson S . Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer. 1996; 77(9):1809-14. DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1809::AID-CNCR8>3.0.CO;2-6. View

16.

Xu X, Garcia M, Li T, Khor L, Gajapathy R, Spittle C . Cytoskeleton alterations in melanoma: aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression. Mod Pathol. 2009; 23(2):187-96. PMC: 2827925. DOI: 10.1038/modpathol.2009.157. View

17.

Neuman H, Patel A, Ishill N, Hanlon C, Brady M, Halpern A . A single-institution validation of the AJCC staging system for stage IV melanoma. Ann Surg Oncol. 2008; 15(7):2034-41. DOI: 10.1245/s10434-008-9915-0. View

18.

Reed R . Minimal deviation melanoma. Hum Pathol. 1990; 21(12):1206-11. DOI: 10.1016/s0046-8177(06)80032-8. View

19.

Swerlick R, Chen S . The melanoma epidemic. Is increased surveillance the solution or the problem?. Arch Dermatol. 1996; 132(8):881-4. DOI: 10.1001/archderm.132.8.881. View

20.

Katsambas A, Nicolaidou E . Cutaneous malignant melanoma and sun exposure. Recent developments in epidemiology. Arch Dermatol. 1996; 132(4):444-50. View